Skip to main content

Novel Rx

      Rheumatology Roundup
      Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
      Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA

      Dr. Robert Chao (Tysons, VA) discusses Abst

      Dr. John Cush RheumNow

      1 year 7 months ago
      Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
      Daily Recap - WEDNESDAY
      Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23

      Feasible after early remission induction https://t.co/

      Dr Gurdeep S Dulay

      1 year 7 months ago
      Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23 Feasible after early remission induction https://t.co/WwiNp8WKDC
      Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN

      Rohit Aggarwal

      1 year 7 months ago
      Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer .Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
      Large French study on infection risk of PsA biologics
      12k pts over 6 years
      When compared to Humira, only Enbrel and Ste

      Robert B Chao, MD

      1 year 7 months ago
      Large French study on infection risk of PsA biologics 12k pts over 6 years When compared to Humira, only Enbrel and Stelara had lower infection risk Concurrent steroid use associated with increased infection 1.85HR @RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progressio

      Dr. Antoni Chan

      1 year 7 months ago
      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
      Continued interest on CAR-T cells in systemic sclerosis!

      6 mo f/up data on 3 pts who received CAR-T cell treatment - st

      Robert B Chao, MD

      1 year 7 months ago
      Continued interest on CAR-T cells in systemic sclerosis! 6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall Skin findings improved in all 3 pts Previous finger ulcerations resolved Lung function stable in 2 pts, improved in 1 @RheumNow #ACR23 Abs#2598
      #ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Pr

      Dr. Rachel Tate

      1 year 7 months ago
      #ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
      Interesting late breaker!
      Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
      Phase 3

      Robert B Chao, MD

      1 year 7 months ago
      Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression No difference in safety profile compared to placebo @RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
      ×